The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
After repeated discussions, the Japanese government concluded that it cannot grant “special approval” for Fujifilm’s antiviral Avigan (favipiravir) for the treatment of COVID-19 under the current law and regulations, Prime Minister Shinzo Abe said on April 28. “Special approval can…
To read the full story
Related Article
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- CMIC Group to Support Clinical Trial, Manufacturing of Avigan for COVID-19 Treatment
April 24, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
- Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
REGULATORY
- Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More
May 15, 2025
- Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
- Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule
May 15, 2025
- Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
- Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…